- "A 바카라 프로그램 that maintains low LDL-C levels long-term... Proven for both efficacy and safety"
- Stresses t바카라 프로그램 importance of managing cardiovascular disease by reducing cumulative LDL-C exposure
[by Yoo, Ha Eun] "LEQVIO (inclisiran sodium) is the first 바카라 프로그램 treatment in Korea that uses 'small interfering RNA (바카라 프로그램)' naturally found in the body to inhibit the production of the 'PCSK9 protein' and reduce 'low-density lipoprotein cholesterol (LDL-C)' levels in the blood. Its efficacy and safety have been demonstrated in three phase 3 clinical trials (ORION-9, ORION-10, ORION-11)."
Novartis Korea announced on January 21 that it hosted a luncheon symposium at the '21st Winter International Conference of the Korean Society of Interventional Cardiology (KSIC 2025),' to highlight the clinical value of 'LEQVIO', the first 바카라 프로그램 treatment approved in Korea.
The luncheon symposium was moderated by Professor Kim Byeong-keuk from the Department of Cardiology at Severance Hospital and Professor Park Duk-woo from the Department of Cardiology at Seoul Asan Medical Center. Professor Michael D. Shapiro of Atrium Health Wake Forest Baptist Medical Center in the United States also participated as a speaker. Professor Shapiro delivered a presentation titled, “How to Manage ACS Patients beyond the Hospital: Integrating 바카라 프로그램 Therapy.”
“The extent to which LDL-C is lowered (the degree of reduction) and how long it remains at low levels (the duration of reduction) are critical factors in reducing the risk of atherosclerotic cardiovascular disease (ASCVD),” Shapiro explained. “LEQVIO uses 바카라 프로그램, which is naturally found in the body to inhibit the production of PCSK9 protein and reduce LDL-C levels in the blood.”
Professor Shapiro explained that since 바카라 프로그램 is administered directly by medical staff twice a year, patients who are afraid of self-injection can manage their LDL-C levels in collaboration with their healthcare providers.
Shapiro also highlighted that only 34% of ASCVD patients maintain a medication adherence rate above 80%, emphasizing that low medication compliance is a current challenge in LDL-C management. He further explained the importance of high medication adherence in lipid-lowering 바카라 프로그램, stating, "If medication compliance is not properly maintained in lipid-lowering 바카라 프로그램, LDL-C variability increases, which raises the average LDL-C burden for patients."
Shapiro also highlighted the three phase 3 clinical trials (ORION-9, ORION-10, ORION-11) of 바카라 프로그램, which were conducted in patients diagnosed with primary hypercholesterolemia, mixed dyslipidemia, or those with equivalent risk or heterozygous familial hypercholesterolemia (HeFH).
According to Shapiro's presentation, 바카라 프로그램 has demonstrated up to a 52% reduction in LDL-C compared to a placebo. In particular, in clinical trials involving Asian patients, including 24% Korean patients, 바카라 프로그램 showed a 60.47% reduction in LDL-C compared to placebo. Additionally, the long-term safety profile of 바카라 프로그램 was confirmed for up to 6.8 years.
Professor Kim Byeong-keuk from the Department of Cardiology at Severance Hospital, who moderated the luncheon symposium, expressed, "The LDL-C target achievement rate for ASCVD patients in 바카라 프로그램, who urgently need cholesterol management, remains below 30%." He added, "As the risk of cardiovascular disease increases with lifetime cumulative LDL-C exposure, it is crucial to manage medication compliance to maintain consistently low LDL-C levels."
"There remains a significant unmet need for lipid-lowering treatment in ASCVD patients whose LDL-C levels are not adequately controlled with the maximum tolerated doses of statins," said Professor Park Duk-woo from the Department of Cardiology at Seoul Asan Medical Center. "With the expansion of LLT treatment options through the launch of new 바카라 프로그램 drugs following PCSK9 inhibitors, we anticipate that these treatment needs will be addressed."